ASCELIA – AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

OUR STORY

Our Vision

Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.

Learn more about us:

Ascelia Pharma company presentation Dec 2021

Q3-2021 investor conference call

EXHIBITION

RSNA 2021 in Chicago

November 28 – December 2

On 1^st December, Dr. Kohkan Shamsi presented the abstract for Orviglance comparison study to gadolinium.

Press release with the study results

RSNA 2021 presentation SSGI12-2 Kohkan Shamsi

View all events

Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with the daily oral chemotherapy candidate drug Oncoral.

2021-12-01

Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Ascelia Pharma AB (publ) (ticker: ACE) today presented results at the world’s largest radiology conference, RSNA, in Chicago, Illinois from the study in which the investigational contrast agent Orviglance® was compared against a gadolinium-based contrast agent.

2021-11-30

Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB

Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 5 May 2022 has been appointed

View all

Presentations

2021-12-07

HC Andersen Capital seminar – Re-read Study Orviglance vs. Gadolinium

CEO Magnus Corfitzen presents results from the re-read study vs. a gadolinium contrast agent (presentation in Danish)

2021-11-25

Erik Penser Bank – Company day

CEO Magnus Corfitzen presents at Erik Penser company day.

2021-11-11

Redeye Life Science Day 2021

Ascelia Pharma CEO Magnus Corfitzen presents at Redeye Life Science Day.

View all

INVESTOR

Shortcut to our latest Financial Reports

IR & Media

PEOPLE

Meet our CEO Magnus Corfitzen

Listen to Ascelia Pharma’s CEO Magnus Corfitzen and the vision and plans for the company

ASCELIA
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

ADVANCING
ORPHAN ONCOLOGY

Our Vision

RSNA 2021 in Chicago

Upcoming Events

Aktiedagen in Lund

Full year report 2021 (January-December 2021)

Erik Penser Banks theme day – Health Care

Latest News

Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial

Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB

Presentations

HC Andersen Capital seminar – Re-read Study Orviglance vs. Gadolinium

Erik Penser Bank – Company day

Redeye Life Science Day 2021

Shortcut to our latest Financial Reports

Meet our CEO Magnus Corfitzen

About us

Meet us

Our values

About us

Pipeline

IR & Media

Contact us

Follow us

ADVANCINGORPHAN ONCOLOGY

Our Vision

RSNA 2021 in Chicago

Upcoming Events

Aktiedagen in Lund

Full year report 2021 (January-December 2021)

Erik Penser Banks theme day – Health Care

Latest News

Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial

Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB

Presentations

HC Andersen Capital seminar – Re-read Study Orviglance vs. Gadolinium

Erik Penser Bank – Company day

Redeye Life Science Day 2021

Shortcut to our latest Financial Reports

Meet our CEO Magnus Corfitzen

About us

Meet us

Our values

ADVANCING
ORPHAN ONCOLOGY